NovaBiotics will be participating in the 40th annual conference of the European Cystic Fibrosis Society (ECFS) in Seville, Spain (7th – 10th June). The NovaBiotics team will be presenting updates on Lynovex and Novamycin as treatments for more common and emerging bacterial lung infections in cystic fibrosis patients. The ECFS conference brings together clinicians, researchers and other stakeholders from the cystic fibrosis community to share advances in basic research, clinical care and the latest in new treatments for cystic fibrosis.

Lynovex is a novel, highly differentiated therapy for the treatment of cystic fibrosis-associated lung disease. Lynovex addresses the key treatment challenges through its unique multi-action: Antibacterial - addressing both current (e.g. Pseudomonas spp) and emerging/antibiotic insensitive (e.g. NTM and Burkholderia Spp) bacterial pathogens; Mucolytic - clear superiority to approved mucolytic therapeutics; Antibiofilm - addressing the key challenge of bacterial colonisation within the airways of cystic fibrosis patients; Chemopotentiation – enhancing the activity of standard of care antibiotics applied for the treatment and management of bacterial infections associated with cystic fibrosis. Together, these drug attributes have the potential for significant positive clinical impact for cystic fibrosis patients. Lynovex is being developed in oral form as an acute, adjunct intervention in cystic fibrosis infectious exacerbations and in inhaled form for long term management of cystic fibrosis lung disease symptomology.

Novamycin is a first-in-class antifungal peptide which is active against more common and emerging fungal pathogens associated with cystic fibrosis lung disease, including Aspergillus fumigatus, Scedosporium and Exophiala spp. Novamycin is being developed for cystic fibrosis in inhaled form to be delivered directly to the site of fungal infection within lung tissue.